Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Get the latest updates from Investor Update directly as they happen.
Follow now 190 followers
Last updated 3 days ago
3 days ago
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust...
6 days ago
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for...
6 days ago
The Roche Investor Relations team would like to invite you to the...
7 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 4% in...
8 days ago
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test...
8 days ago
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than...
9 days ago
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will...
10 days ago
The pivotal phase IIb ALIENTO study met the primary endpoint of a...
13 days ago
Basel, 18 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
14 days ago
Roche will publish its Half Year Results of 2025 prior to the...
about 1 month ago
Roche will publish its Half Year Results of 2025 prior to the...
about 1 month ago
Positive phase I/II data presented at the 2025 International Society on Thrombosis...